In a changing healthcare landscape, delivering value requires true vision.
Adamis is currently developing products in various therapeutic areas including respiratory disease, allergy and opioid overdose. Adamis will pursue 505 (b) (2) regulatory approval filings whenever possible in order to minimize costs and shorten the time to market. The focus is to create high quality, lower-cost therapeutic alternatives to existing treatments.
|PRODUCT NAME1||TYPE||POTENTIAL INDICATION||PHASE 1||PHASE 2||PHASE 3||NDA||APPROVED|
|SYMJEPI® (epinephrine)2 Injection 0.3mg||Injectable||Anaphylaxis|
|SYMJEPI® (epinephrine)2 Injection 0.15mg||Injectable||Anaphylaxis|
|ZIMHI™(naloxone)2,3 Injection 5mg||Injectable||Opioid Overdose|
|APC-400 (tempol)4 Topical Gel||Topical||Radiation Dermatitis|
|Oral||Respiratory Disease / Anti-Inflammatory|
|APC-1000 (beclomethasone)6 Metered Dose Inhaler||Inhaler||Asthma|
|APC-4000 (fluticasone)7 Dry Powder Inhaler||Inhaler||Asthma|
1 Represents the next development/regulatory stage Adamis intends to pursue 2 Licensed U.S. commercial rights to US WorldMeds 3 FDA action date (PDUFA) November 2020 4 Phase II completed, Phase III ready 5 Phase II/III ready 6 FDA approved Phase III study, development suspended to prioritize other products. 7 Development suspended to prioritize other products.